Study demonstrated 99.6% probability of SGLT-2 inhibitors being the optimal treatment for reducing the risk of HF outcome, followed by GLP-1 agonists (0.27%) and DPP-4 inhibitors (0.1%) [7]. This evidence concerns the gene DPP4 and hydrops fetalis.